Who Needs Monitoring for Tysabri-Related PML?

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

Understanding the Shift from General Health to Specific Risk

If you or a loved one is taking Tysabri, you may have heard about the risk of progressive multifocal leukoencephalopathy (PML)—a rare but serious brain infection. Decades of pharmacovigilance data have established that certain factors, such as JC virus antibody status and longer treatment duration, significantly increase PML risk. This page reviews the patterns reported in medical literature to help you understand who may need closer monitoring.

Bridging to Clinical Evidence: Tysabri and PML Risk

Building on the understanding that Tysabri carries a significant risk of PML, it is crucial to examine the clinical evidence underlying this association. Tysabri (natalizumab) is a monoclonal antibody indicated for the treatment of multiple sclerosis and Crohn's disease. Its use is associated with a significantly increased risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic viral infection of the brain caused by the JC virus (JCV). PML typically occurs in immunocompromised individuals and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The clinical presentation of PML can be variable, often mimicking multiple sclerosis relapses, which complicates diagnosis. Common symptoms include progressive neurological deficits such as weakness, sensory loss, visual disturbances, cognitive decline, and ataxia. Diagnosis relies on brain MRI, which may show characteristic white matter lesions, and detection of JCV DNA in cerebrospinal fluid. Because of the overlap with multiple sclerosis symptoms, an MRI scan should be obtained prior to initiating Tysabri therapy to help differentiate subsequent multiple sclerosis symptoms from PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Mechanism and Risk Factors for Tysabri-Associated PML

The mechanistic pathway linking Tysabri to PML involves its pharmacological action. Tysabri binds to alpha-4 integrins on the surface of immune cells, preventing their migration across the blood-brain barrier. This reduces inflammation in the central nervous system but also impairs immune surveillance, allowing latent JCV to reactivate and cause PML. Three established risk factors for PML in Tysabri-treated patients are: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The prognosis for patients who develop PML while on Tysabri is poor. The boxed warning states that PML "usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). In clinical trials, PML occurred in three patients: two among 1869 multiple sclerosis patients treated for a median of 120 weeks (both had also received interferon beta-1a), and one among 1043 Crohn's disease patients after eight doses (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Long-term outcomes for survivors often include persistent neurological deficits, though some patients may stabilize with immune reconstitution.

Prognosis and Long-Term Outcomes After PML Diagnosis

The timeline between Tysabri exposure and PML onset can vary; cases have been reported after as few as eight doses and after more than two years of treatment. Importantly, PML has also been reported following discontinuation of Tysabri in patients who did not have findings suggestive of PML at the time of discontinuation. Therefore, patients should continue to be monitored for any new signs or symptoms that may be suggestive of PML for at least six months following discontinuation of Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The adequacy of warnings regarding Tysabri and PML is addressed through a boxed warning and a restricted distribution program called the TOUCH Prescribing Program. The boxed warning clearly states that Tysabri increases the risk of PML and that risk factors include anti-JCV antibodies, duration of therapy, and prior immunosuppressant use. It instructs healthcare professionals to monitor patients for any new sign or symptom suggestive of PML and to withhold Tysabri immediately at the first sign or symptom (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The TOUCH program restricts distribution to prescribers and patients who are enrolled and comply with monitoring requirements (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these measures, PML remains a serious risk, and the prognosis for affected patients is grave. Prognosis-related considerations for affected patients include the need for early detection and management. Because PML usually leads to death or severe disability, prompt recognition and discontinuation of Tysabri are critical. However, even with early intervention, many patients experience irreversible neurological damage. The timeline between exposure and documented harm can be prolonged, with PML occurring after months to years of treatment, and even after drug cessation. This underscores the importance of ongoing vigilance and risk stratification based on anti-JCV antibody status and treatment duration. In summary, Tysabri-associated PML carries a poor prognosis, with most cases resulting in death or severe disability. The risk is heightened by anti-JCV antibodies, longer treatment duration, and prior immunosuppressant use. While warnings and monitoring programs are in place, the devastating nature of PML necessitates careful risk-benefit assessment before initiating and continuing Tysabri therapy.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.

Frequently Asked Questions

What is the long-term prognosis for patients who develop PML after Tysabri?

The prognosis is generally poor. The boxed warning states that PML 'usually leads to death or severe disability' (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Survivors often have persistent neurological deficits, though some may stabilize with immune reconstitution.

What are the main risk factors for developing PML while on Tysabri?

Three established risk factors are: presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

How is PML diagnosed in Tysabri-treated patients?

Diagnosis relies on brain MRI showing characteristic white matter lesions and detection of JCV DNA in cerebrospinal fluid. Because symptoms can mimic MS relapses, an MRI should be obtained before starting Tysabri to help differentiate subsequent symptoms (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed Tysabri Label

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.